Literature DB >> 9650125

Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy.

N Ahsan1.   

Abstract

Since the early 1950s, intravenous immunoglobulin (IVIG) preparations are being used in the treatment of hematologic, neurologic, nephrologic, autoimmune, and immunodeficiency disorders. Infusion of IVIG preparations may cause osmotic-induced acute renal failure. Despite the fact that this entity has been reported previously, it is not a widely appreciated complication. A total of 22 reports involving 52 patients in whom renal failure occurred in association with IVIG infusion. The patients' ages ranged from 20 to 82 years. Thirty patients had preexisting renal insufficiency. Rise in serum creatinine was noted after 1-10 days of IVIG infusion and creatinine returned to baseline within 2-60 days of discontinuation. One developed end stage renal disease. There were four fatalities related to complications of renal failure. Histopathology of renal tissue showed osmotically induced tubular injury (5 patients), tubular vacuolization (2 patients), tubulointerstitial infiltrate (1 patient), and cryoglobulin deposits (1 patient). There appears to be no direct relationship between the development of acute renal failure and the type of IVIG. However, underlying renal insufficiency increases the risk of renal failure. In view of the increasing use of IVIG preparations in medicine, it is imperative that clinicians be aware of this unusual form renal injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9650125

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  8 in total

Review 1.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 2.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 3.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

Review 4.  Immunoglobulin replacement therapy in children.

Authors:  Maria Garcia-Lloret; Sean McGhee; Talal A Chatila
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

5.  Role of Laparoscopic Splenectomy in Elderly Immune Thrombocytopenia.

Authors:  Valentina Giudice; Rosa Rosamilio; Bianca Serio; Rosa Maria Di Crescenzo; Francesca Rossi; Amato De Paulis; Vincenzo Pilone; Carmine Selleri
Journal:  Open Med (Wars)       Date:  2016-11-19

6.  The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis.

Authors:  Jie Cui; Xuxia Wei; Haijin Lv; Yuntao Li; Ping Li; Zhen Chen; Genglong Liu
Journal:  Ann Intensive Care       Date:  2019-02-06       Impact factor: 6.925

Review 7.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

Review 8.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.